癌细胞表达的信号淋巴细胞激活分子家族成员7（SLAMF7）是否会影响CD47介导的吞噬作用？
Does cancer cell-expressed SLAMF7 impact on CD47-mediated phagocytosis?
作者信息
Bouwstra Renee, van Meerten Tom, Bremer Edwin
机构信息
Department of Hematology, University of Groningen, University Medical Center Groningen (UMCG), Groningen, The Netherlands.
出版信息
Mol Cell Oncol. 2019 Apr 16;6(3):1600349. doi: 10.1080/23723556.2019.1600349. eCollection 2019.
Abstract
Innate immune checkpoint CD47 has emerged as a prominent target for cancer immunotherapy and defining biomarkers predictive of response will be a crucial step towards clinical implementation. Hereto, we investigated the importance of a previously reported requisite for SLAM family member 7(SLAMF7) expression on cancer cell phagocytosis for effective CD47 antibody therapy.
摘要
固有免疫检查点CD47已成为癌症免疫治疗的一个重要靶点，确定预测反应的生物标志物将是迈向临床应用的关键一步。在此，我们研究了先前报道的SLAM家族成员7（SLAMF7）表达对于癌细胞吞噬作用在有效CD47抗体治疗中的必要性的重要性。
相似文献
1
Does cancer cell-expressed SLAMF7 impact on CD47-mediated phagocytosis?
Mol Cell Oncol. 2019 Apr 16;6(3):1600349. doi: 10.1080/23723556.2019.1600349. eCollection 2019.
2
Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis.
Nat Commun. 2019 Feb 1;10(1):533. doi: 10.1038/s41467-018-08013-z.
3
SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin.
Nature. 2017 Apr 27;544(7651):493-497. doi: 10.1038/nature22076. Epub 2017 Apr 19.
4
Cancer immunotherapy targeting the CD47/SIRPα axis.
Eur J Cancer. 2017 May;76:100-109. doi: 10.1016/j.ejca.2017.02.013. Epub 2017 Mar 10.
5
The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
Immunol Rev. 2017 Mar;276(1):145-164. doi: 10.1111/imr.12527.
6
CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL.
Cancer Immunol Res. 2019 Oct;7(10):1663-1671. doi: 10.1158/2326-6066.CIR-18-0781. Epub 2019 Aug 13.
7
CD47: the next checkpoint target for cancer immunotherapy.
Crit Rev Oncol Hematol. 2020 Aug;152:103014. doi: 10.1016/j.critrevonc.2020.103014. Epub 2020 Jun 2.
8
Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint.
J Immunother Cancer. 2019 Dec 4;7(1):340. doi: 10.1186/s40425-019-0772-0.
9
CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises.
Future Oncol. 2018 Sep;14(21):2179-2188. doi: 10.2217/fon-2018-0035. Epub 2018 Apr 18.
10
SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy.
Trends Immunol. 2018 Mar;39(3):173-184. doi: 10.1016/j.it.2017.12.005. Epub 2018 Jan 11.
引用本文的文献
1
Emerging roles of SLAMF7 in immune cells and related diseases.
Innate Immun. 2025 Jan-Dec;31:17534259251326700. doi: 10.1177/17534259251326700. Epub 2025 Mar 16.
2
Targeting Myeloid Checkpoint Molecules in Combination With Antibody Therapy: A Novel Anti-Cancer Strategy With IgA Antibodies?
Front Immunol. 2022 Jul 5;13:932155. doi: 10.3389/fimmu.2022.932155. eCollection 2022.
3
Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies.
J Clin Med. 2020 Sep 4;9(9):2864. doi: 10.3390/jcm9092864.
4
Recent updates on CAR T clinical trials for multiple myeloma.
Mol Cancer. 2019 Nov 5;18(1):154. doi: 10.1186/s12943-019-1092-1.
本文引用的文献
1
Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis.
Nat Commun. 2019 Feb 1;10(1):533. doi: 10.1038/s41467-018-08013-z.
2
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.
N Engl J Med. 2018 Nov 1;379(18):1711-1721. doi: 10.1056/NEJMoa1807315.
3
Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy.
Nat Immunol. 2018 Jan;19(1):76-84. doi: 10.1038/s41590-017-0004-z. Epub 2017 Nov 27.
4
SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin.
Nature. 2017 Apr 27;544(7651):493-497. doi: 10.1038/nature22076. Epub 2017 Apr 19.
5
CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer.
J Clin Invest. 2016 Jul 1;126(7):2610-20. doi: 10.1172/JCI81603. Epub 2016 Jun 13.
6
Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47.
Sci Transl Med. 2010 Dec 22;2(63):63ra94. doi: 10.1126/scitranslmed.3001375.
7
Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma.
Cell. 2010 Sep 3;142(5):699-713. doi: 10.1016/j.cell.2010.07.044.
Zotero 插件